Alzheimer’s Benefits Continue With Donanemab for 3 Years, Long-Term Data Show

By News Health
2 months Ago

(MedPage Today) — TORONTO — The clinical benefits of donanemab (Kisunla) continued over 3 years in people with early symptomatic Alzheimer’s disease, data from the long-term extension of the TRAILBLAZER-ALZ 2 trial suggested.
Compared with…

Source link : https://www.medpagetoday.com/meetingcoverage/aaic/116791

Author :

Publish date : 2025-08-01 18:42:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Which Docs Are Leaving the Workforce in Greater Numbers?

Where Are U.S. Antibiotics Originating? Aldosterone and Heart Disease Risk

Pronatalism and Public Health Are Incompatible

Poor Heart Health in Youth Linked With Later Pregnancy Risks

Report shows 'stark' gender gap in HIV prevention across West Midlands

GLP 1s and Libido: An Effect That May Fly Under the Radar